alxn2030
Nucleic acidexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 16, 2022 (NCT05501717)
Timeline
Indications
Mechanism of action
- C3AINHIBITOR
C3A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06744647 | Phase 2 | Mar 25, 2025 | Alexion |
| NCT05501717 | Phase 1 | Aug 16, 2022 | Alexion |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexion | For profit | 2 | 2 | 2 | 2022 |
1 organizations
Page 1 / 1